739 results on '"Kümpfel, Tania"'
Search Results
2. Evolution of retinal degeneration and prediction of disease activity in relapsing and progressive multiple sclerosis
3. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management
4. A genome-wide in vivo CRISPR screen identifies essential regulators of T cell migration to the CNS in a multiple sclerosis model
5. Single cell transcriptomics of cerebrospinal fluid cells from patients with recent-onset narcolepsy
6. [18F]F-DED PET imaging of reactive astrogliosis in neurodegenerative diseases: preclinical proof of concept and first-in-human data
7. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis
8. Impact of adult-onset multiple sclerosis on MRI-based intracranial volume: A study in clinically discordant monozygotic twins
9. Patient-reported outcome parameters and disability worsening in progressive multiple sclerosis
10. Persistent virus-specific and clonally expanded antibody-secreting cells respond to induced self-antigen in the CNS
11. Peripapillary hyper-reflective ovoid mass-like structures (PHOMS) in AQP4-IgG-positive neuromyelitis optica spectrum disease (NMOSD) and MOG-IgG-associated disease (MOGAD)
12. Distinct molecular profiles of skull bone marrow in health and neurological disorders
13. Glutamic acid decarboxylase antibody-associated neurological syndromes: Clinical and antibody characteristics and therapy response
14. Twin study reveals non-heritable immune perturbations in multiple sclerosis
15. SARS-CoV-2 antibody seroprevalence in a large neuroimmunological patient cohort
16. First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine
17. Cross-reactivity of a pathogenic autoantibody to a tumor antigen in GABA A receptor encephalitis
18. Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity
19. The effects of transcranial direct current stimulation on sleep in patients with multiple sclerosis–A pilot study
20. Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice
21. Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study
22. Intramuscular vaccination against SARS-CoV-2 transiently induces neutralizing IgG rather than IgA in the saliva
23. Immune signatures of prodromal multiple sclerosis in monozygotic twins
24. Skin and gut imprinted helper T cell subsets exhibit distinct functional phenotypes in central nervous system autoimmunity
25. Schmerzen bei multipler Sklerose und Neuromyelitis-optica-Spektrum-Erkrankungen
26. Von der Neuromyelitis optica zur Neuromyelitis-optica-Spektrum-Erkrankung: vom klinischen Syndrom zur Klassifikation
27. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial
28. Explorative study of emerging blood biomarkers in progressive multiple sclerosis (EmBioProMS): Design of a prospective observational multicentre pilot study
29. Pathomechanisms in demyelination and astrocytopathy: autoantibodies to AQP4, MOG, GFAP, GRP78 and beyond
30. Amino Acid Uptake, Glucose Metabolism, and Neuroinflammation in John Cunningham Virus Associated Progressive Multifocal Leukoencephalopathy
31. Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis
32. Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well?
33. Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders
34. Retinal axonal degeneration in Niemann–Pick type C disease
35. Bifrontal transcranial direct current stimulation modulates fatigue in multiple sclerosis: a randomized sham-controlled study
36. Antibody signatures in patients with histopathologically defined multiple sclerosis patterns
37. CSF Findings in Acute NMDAR and LGI1 Antibody–Associated Autoimmune Encephalitis
38. Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis: Real-world Evidence From the GENERATE Registry
39. Is there an immunological cross-reactivity of antibodies to the myelin oligodendrocyte glycoprotein and coronaviruses?
40. Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis.
41. Effects of Natalizumab Therapy on Intrathecal Immunoglobulin G Production Indicate Targeting of Plasmablasts
42. Differential Binding of Autoantibodies to MOG Isoforms in Inflammatory Demyelinating Diseases
43. Therapy challenges for NMOSD in a patient with HIV
44. Inner Retinal Layer Changes Reflect Changes in Ambulation Score in Patients with Primary Progressive Multiple Sclerosis
45. Inpatient care of neuromyelitis optica spectrum disorder in Germany: Nationwide analysis from 2010 to 2021
46. Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases
47. Longitudinal prevalence and determinants of pain in multiple sclerosis: results from the German National Multiple Sclerosis Cohort study
48. Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS)
49. Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: A cohort study from Germany
50. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.